GHRH Inhibition Worsens Acetaminophen-Induced Liver Damage in Mice
Background
Acetaminophen (APAP) overdose is a leading cause of acute liver injury and acute liver failure worldwide, posing a significant clinical challenge. While the mechanisms of APAP toxicity are well-studied, the full extent of hormonal regulation in liver damage progression remains unclear. Specifically, the role of growth hormone-releasing hormone (GHRH) and its downstream effects on the GH/IGF-I axis (Growth Hormone/Insulin-like Growth Factor-I axis), which is known to influence liver health and regeneration, has not been thoroughly investigated in the context of APAP-induced hepatotoxicity. This study aimed to elucidate how inhibiting GHRH impacts the severity of acetaminophen-induced acute liver injury in mice.
Results
The study revealed that inhibiting GHRH significantly exacerbated the severity of acetaminophen-induced acute liver injury. Mice treated with the GHRH inhibitor showed markedly elevated levels of serum liver enzymes, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), indicating greater hepatocyte damage compared to APAP-only treated controls. Histopathological examination confirmed these findings, demonstrating more extensive areas of liver necrosis and increased inflammatory cell infiltration in the GHRH-inhibited group. > The most critical finding was that GHRH inhibition led to a significant aggravation of liver injury, which was directly linked to a downregulation of the GH/IGF-I axis, specifically resulting in reduced IGF-I levels, a key mediator of growth and tissue repair. This suggests that the normal functioning of the GH/IGF-I axis plays a protective role against APAP toxicity, and its disruption by GHRH inhibition removes this crucial defense mechanism, leading to worsened outcomes.
Why It Matters
This research highlights the critical protective role of GHRH and the downstream GH/IGF-I axis in mitigating acute liver injury caused by acetaminophen. The findings suggest that maintaining or enhancing GHRH signaling could be a viable strategy to protect the liver from toxic insults. Understanding this pathway opens new avenues for therapeutic development, as modulating the GH/IGF-I axis could potentially offer a novel approach to treat or prevent drug-induced liver damage. Future investigations could explore GHRH agonists or IGF-I supplementation as potential clinical interventions for patients at risk of or suffering from acute liver injury, warranting further studies, including human trials.